← Azimuth Daily
Capturing data…
Capturing data…
SAT, 17 OCT · 80 ITEMS
"Phase 1 trial of EGFR-targeted antibody-toxin conjugate shows promise in recurrent glioma" — Nature Medicine · Science & Medicine
This is a report of a Phase 1 clinical trial testing an that targets (a receptor often amplified/overexpressed in gliomas) in patients with recurrent , presented as showing promising early results. An antibody-toxin conjugate (a type of immunotoxin) combines an EGFR-binding antibody with a toxic payload to kill tumor cells; Phase 1 primarily evaluates safety, dosing, and tolerability, so 'promise' reflects preliminary efficacy signals that still need later-phase confirmation.
The claim is a primary-source report (the actual Nature Medicine paper), so it accurately reflects the trial's own stated findings. Phase 1 trials, however, are small, early-stage, and safety-focused; any efficacy hints are provisional and not yet proof of a therapeutic benefit. Search results show older, similar trials (e.g., an intracerebral EGFR-targeted toxin study from 2008), so this appears to be a distinct, newer trial rather than a resurfacing of prior work.
Genuinely new: the report is described as a current Nature Medicine publication with no recirculation year given.
We covered a separate of intracranial CAR-T cells for recurrent glioblastoma in August 2026 — a different approach but the same patient population.